Introduction
The appearance of human tumors is the result of a complex, multiple-step process. Events involved in each step are a series of mutations of cellular genes that has been demonstrated in the carcinogenesis of colorectal cancer (Vogelstein and Kinzler, 1994) . The formation of other human neoplasms presumably follows a similar process. In most tumors and hematopoietic malignancies, the early event of carcinogenesis is the appearance of abnormal chromosome numbers (aneuploidy) and the loss of heterozygosity (LOH) at many genetic loci .
Chromosomal aneuploidy is the result of the improper distribution of two chromatids of a chromosome to daughter cells during mitosis. Normally the process is under the surveillance of the mitosis checkpoint that ensures proper assembly of the mitotic spindle. The genes involved in the mitosis checkpoint have been identified in the yeast. These consist of Bub (budding uninhibited by benomyi) 1, Bub2, and Bub3 and Mad (mitosis arrest deficiency) 1, Mad2, and Mad3, and Mpsl (Hoyt et al., 1991; Li and Murray, 1991) . In mammalian cells the BUB1 and MAD2 proteins are detected at the centromere region in the prophase of mitosis, but not after stable microtubule attachments are made at metaphase (Taylor and Mckeon, 1997; Li and Benezra, 1996) .
In aneuploid colorectal tumor cell lines it was found to maintain chromosomal instability (CIN) (Lengauer et al., 1997) . A small fraction of colorectal tumors with CIN was later found to be due to the defective surveillance at the spindle assembly checkpoint and this was found to be due to mutations in the hBUB1 gene (Cahill et al., 1998) . Furthermore, only one copy of the hBUB1 gene is mutated in CIN colorectal cancer, suggesting that mutant alleles act dominantly or alternatively, that a single normal copy is insufficient for normal functions.
If the observation that defective mitosis checkpoint genes can contribute to CIN in colorectal cancers at the early stage of tumor progression, then it should be expected that defects in some of these mitosis checkpoint genes will play a role in chromosomal aneuploid of other types of tumors. With this assumption in mind we examined the hBUB1 gene in breast cancer cells, leukemia cell lines, and leukemia and lymphoma cells from patients, since these cells have a very high frequency of chromosomal abnormality. Our results showed that most of the breast cancer cell lines we studied have a normal hBUB1 gene. Among the leukemia cells we detected small deletions in hBUB1 coding sequence in lymphoid leukemia and lymphoma cells.
Results

Generation of hBUB1 cDNA by RT -PCR
The coding sequence of hBUB1 gene contains 3150 nucleotides with 5' end (or N terminal) of cDNA possessing the ability to attach to kinetochore, thus designated as the kinetochore localization domain. The 3' end of the cDNA contains kinase activity that can phosphorylate one of the mitotic checkpoint complex hBUB3, thus designated as the kinase domain ( Figure  1 ). To generate hBUB1 cDNA for sequence analysis three overlapping pairs of primers were designed that covered the kinetochore localization, central and kinase domains. These primers were used in PCR to generate hBUB1 cDNA fragments. Each fragment has an internal EcoR1 site for easy identification of the PCR product.
hBUB1 cDNA in breast cancer cell lines Quite a few human solid tumors have aneuploid chromosomes, therefore we first examined hBUB1 cDNA among several breast cancer cell lines. Total RNA was extracted from several breast cancer cell lines. RT -PCR was carried out to generate cDNA fragments (A, B, and C) covering the entire coding sequence of the hBUB1 gene. These cDNAs were digested with EcoR1 and analysed by electrophoresis in agarose gel. The A, B, and C cDNA fragments of the hBUB1 gene from the examined breast cancer cell lines did not show discernible deletions. Sequence analysis of these fragments also did not reveal small deletions or mutations except those polymorphic sites reported (Cahill et al., 1999) . Therefore among breast cancer cell lines we have examined, MCF7, MB231, MB435, MB453, T47D, MB474 and MB483, we did not detect defects of the hBUB1 gene.
hBUB1 cDNA in leukemia cell lines
Since leukemia cell lines frequently have chromosomal abnormalities, we therefore analysed the hBUB1 cDNA derived from several leukemia cell lines. A fragment of hBUB1 cDNA contained an EcoR1 site. When the PCR products were digested with EcoR1 and analysed by agarose gel electrophoresis they should generate two fragments: one at the 3' end of A fragment with a size of 839 bp and another at the 5' end of A fragment with a size of 382 bp. As shown in Figure 2 three lymphoid leukemia cells HL60, H9 and CEM have a normal size. In contrast the blast cell line derived from CML, K562, showed a deletion around the HindIII site of the A fragment. The lymphoid cell line Molt3 contained a deletion at the 5' end of the A fragment. Two subclones of the other lymphoid cell line Molt4 had two different deletion lesions: one at the 5' end and another at the 3' end of the A fragment.
Sequence analysis showed that Molt3 has a deletion of 69 bp (NT 26 -94) near the 5' end of the A fragment of hBUB1. Molt4A3 has a deletion of 81 bp at the internal of the A fragment. In addition Molt4A3 has a point mutation at the HindIII site of the A fragment. The results were summarized in Figure 3 .
B and C fragments of hBUB1 cDNA from these leukemia cell lines were also digested with EcoR1 and subsequently analysed by gel electrophoresis. As shown in Figure 4 , there were no gross deletions of these Figure 1 Functional domains of hBUB1 cDNA. The N-terminal third is the kinetochore localization domain and the C-terminal third is the kinase domain Figure 2 The A fragment of hBUB1 cDNA from leukemia cell lines. The RT -PCR products from various leukemia cell lines were cloned, purified, digested with EcoR1, and analysed by agarose gel electrophoresis. Normal sizes of hBUB1 cDNA fragments after EcoRI digestion should generate 839 bp and 382 bp as indicated by arrows Figure 3 Lesions of deletions and mutation of kinetochore binding domain (or A fragment) of hBUB1 cDNA in leukemia cell lines. The triangles indicate the location of deletion and the number of base pairs deleted. In Molt4A3 point mutation at the HindIII site was indicated. ND: not done fragments of the hBUB1 cDNA derived from these cell lines. Sequence analysis of these DNA fragments did not detect small deletion or discernible mutation. We have also analysed hBUB1 cDNA derived from myeloid leukemia cell lines KG1 and KG 1a. We did not detect any deletion or mutations of the hBUB1 gene in these two cell lines. Thus the defective lesions detected in the lymphoid cell lines were confined in the kinetochore localization domain of the hBUB1 gene.
hBUB1 cDNA from leukemia and lymphoma cells from patients
The detected defects of the hBUB1 gene were from cell lines. It is possible that these defects could be artificially created after the generation of in vitro cultures. We therefore examined the hBUB1 cDNA derived from malignant cells of lymphoid leukemia or lymphoma patients. We had analysed two cases of pediatric acute lymphoblastic leukemia (ALL), two cases of pediatric Hodgkin lymphoma, two pediatric acute myeloid leukemia (AML) samples, and one CML sample. As shown in Figure 5 , one of the ALL samples had no discernible deletion of the hBUB1 gene; another ALL patient sample however showed deletion at the 3' end of the A fragment of hBUB1 cDNA. Tumor cells from two Hodgkin's lymphoma patients showed deletions: one at the 5' end and another at the 3' end of the A fragment of hBUB1 cDNA. The B and C fragments of hBUB1 cDNAs from these patients did not show deletions or mutations. Cells from two AML patients and one CML patient did not show defect at the hBUB1 gene.
To determine whether both copies of the hBUB1 gene were defective, we designed primers flanking the deletion lesion involved in exon 7, intron 7, and exon 8 of the gene and carried out PCR with leukemia cell DNA from a T-ALL patient sample (ALL2 in Figure  5 ) as a template. The normal PCR product should be 320 bp, whereas a deletion should generate a 160 bp DNA. As shown in Figure 6 , the resulting PCR product from normal samples has only 320 bp DNA (the 220 bp appears to an artifact seen in all three samples) whereas ALL2 generated both 320 bp and a b Figure 4 The B and C fragments of hBUB1 cDNA derived from leukemia cell lines. The RT -PCR products of hBUB1 cDNA's B and C fragments from leukemia cell lines were analysed as in Figure 2 . The normal sizes of B and C fragments of hBUB1 cDNA after EcoRI digestion were indicated by arrows Figure 5 The A fragment of hBUB1 cDNA derived from cells of leukemia and lymphoma patients. hBUB1 cDNA A fragment from T-ALL and Hodgkin's disease patients were analysed as in Figure 2 . The sizes of normal hBUB1 cDNA fragments after EcoR1 digestion were indicated by arrows. HD: Hodgkin's disease. ALL: Acute lymphoblastic leukemia hBUB1 and T cell neoplasia HY Ru et al 160 bp DNA. Thus the defect seen in T-ALL2 appeared to be heterozygous in nature.
Effect of hBUB1 defects on the mitosis of leukemia cells
The deletions in the kinetochore localization domains of the hBUB1 gene in lymphoid leukemia and lymphoma cells may contribute to their CIN characteristics. We therefore examined the mitotic indices of HBL100, Molt3 and Molt4. As shown in Figure 7 , the mitotic indices of Molt3 and Molt4 were lower than that of HBL100. It has been shown in colorectal cancer with CIN that the mutant hBUB1 gene behaved dominantly (Cahill et al., 1998) . We therefore constructed our deletion version of hBUB1 cDNA and inserted into eukaryotic expression vector pcDNA3. The vectors expressing either wild type or mutant hBUB1 cDNA were transfected into HBL100. The mitosis indices of transfected cells were examined. As shown in Figure 8 , cells expressing mutant hBUB1 cDNA had a significantly lower mitosis index than those expressing wild type hBUB1 cDNA. We have carried out cell cycle analysis by flow cytometry and cells used in these experiments (MB 100, Molt3 and Molt4) continue to cycle in the presence of nocodazole. These results indicated that defective hBUB1 cDNA behave in a dominant negative fashion, similar to the mutant hBUB1 from colorectal cancer cells with CIN.
Localization of hBUB1 and interaction between hBUB1 and hBUB3
In order to explain the dominant negative effect of the hBUB1 mutant we have used antibody staining to localize the hBUB1. The antibody was prepared against the hBUB1 kinetochore localization domain. As shown in Figure 9 the fluorescent spots were detected in metaphase nuclei, whereas no fluorescent spots were detected when normal serum was used. Furthermore binding experiments were carried out to show the interaction between hBUB1 and hBUB3. As shown in Figure 10 the wild type protein representing the hBUB1 kinetochore localization could bind to GST-hBUB3 protein. In contrast the mutant hBUB1 protein bound to GST-hBUB3 protein with much less efficiency. These results suggested that reduction of Figure 6 Genomic PCR products involving the A fragment of hBUB1 deletion lesion of a T-ALL patient. Genomic DNA samples were used as templates with primers covering the 5' end of exon 7 and the 3' end of exon 8 of hBUB1 gene to carry out PCR. The products were analysed by electrophoresis in 2% agarose gel. M: 100 bp DNA ladder, 1: ALL2, 2: Normal, and 3: ALL1 
Discussion
In most of the solid tumors and hematopoietic malignancies chromosomal aneuploidy that contributes to chromosomal instability (CIN) is a frequently observed phenomenon (Loeb, 1991; Hartwell, 1992) . The molecular basis of CIN in human neoplasia has only started to be unraveled. This was lifted from the studies in yeast. There are many genes in yeast, when altered, that will lead to CIN. One group of genes is the checkpoint genes that ensure the proper progression of the cell cycle (Hoyt et al., 1991; Li and Murray, 1991) . In yeast the products of mitotic spindle checkpoint genes ensure that chromatids will not separate till chromosomes are properly aligned along the mitotic spindle. When one of these genes is damaged, the defective cells will complete mitosis in the presence of a lagging chromosome, resulting in abnormal chromosomal segregation (Murray, 1995; Nasmyth, 1996; Elledge, 1996) . In human neoplasia evidence has also suggested that altered mitotic spindle checkpoint genes contribute to CIN. For example, it has been reported that reduced expression of hMAD2 in breast cancers might contribute to aneuploidy (Li and Benezra, 1996) and there are somatic mutations in the hBUB1 gene in small fractions of colorectal cancers (Cahill et al., 1998 ). In our studies of possible defects of the hBUB1 gene in breast cancer cell lines, with or without chromosomal aneuploidy, we did not detect either mutations or deletion of the hBUB1 gene in breast cancer cell lines. Since there are at least seven mitotic spindle checkpoint genes (i.e. hBUB1-3, hMAD1-3, and hMPS) involved in monitoring proper mitosis progression, damage in one of these genes will contribute to chromosomal aneuploidy. Therefore it is not surprising that we did not detect defects in the hBUB1 genes in breast cancer cell lines. Perhaps damage or reduced expression of other checkpoint genes, such as, hMAD2 is the culprit for the aneuploidy in breast cancer cells (Li and Benezra, 1996) . When investigating the status of hBUB1 gene in leukemia cell lines, we detected deletions in lymphoid leukemia cell lines Molt3 and Molt4, and CML blast cell line K562. In addition we detected a point mutation, a T to C transition in Molt4. The deletions in Molt3 and Molt4 rendered the hBUB1 protein nonfunctional. All the defective lesions are in the kinetochore localization domain of the hBUB1 cDNA. Because of these defects in the hBUB1 gene, the ability of the mitotic spindle complex to monitor the proper alignment of chromatids would be in doubt with the subsequent result of chromosomal instability. It is intriguing to note that only Molt3, Molt4, and K562 have defective hBUB1 genes. In other lymphoid cell lines like CEM and H9, we did not detect abnormal hBUB1 genes. Neither did we detect abnormality of the hBUB1 gene in promyelocytic cell lines HL60 or myelogenous cell lines KG1 and KG 1a. It is very likely that aneuploidy of some of these cell lines is caused by defects of one of the processes involved in chromosome segregation during mitosis.
The results on the hBUB1 gene in the cell lines led us to examine leukemia and lymphoma cells from patients. Our finding showed that the defective hBUB1 gene was detected in smaller fractions of pediatric ALL patients and in Hodgkin's lymphoma patients. The defect of the hBUB1 gene mimicked the finding in the leukemia cell lines, i.e. defects are confined to the kinetochore localization domain of the hBUB1 gene. Furthermore the defects are somatic and heterozygous in nature. No hBUB1 abnormality was detected in two cases of AML and one case of CML. These results seem to suggest that the hBUB1 defect is confined in certain lymphoid leukemia and lymphoma, however a definitive conclusion required an examination of far more cases of clinical samples.
Defects of the mitotic spindle checkpoint will render cells unable to inhibit entry into S phase, when mitosis cannot be completed. Thus instead of arrest in metaphase the aneuploid cells, when treated with spindle-disrupting nocodazole, will prematurely exit from mitosis and start a new round of DNA synthesis. Consequently the mitotic index of aneuploid cells will be lower than that of normal cells. Indeed the mitotic index analysis of the leukemia cell lines showed that Molt3 and Molt4 have lower mitotic index than other cell lines. This is in corroboration with the fact that they have a defective hBUB1 gene. A lower mitotic index in Molt3 and Molt4 is not due to the action of earlier checkpoints such as Chfr (Scolnick and Halazonetis, 2000) because our flow cytometry to analyse the cell cycle of these cells showed that the cycle was not arrested in the presence of nocodazole. In addition, when the defective hBUB1 cDNA from Molt3 was ectopically expressed in cells with normal ploidy, the transfected cells have a lower mitotic index, a behavior similar to aneuploid cells. Similar results were also obtained in the defective hBUB1 from Molt4. This result showed that defective hBUB1 cDNA from Molt3 functions like a dominant negative mutant, similar to a previous report of hBUB1 mutant from colorectal cancer. Defects in the kinetochore localization domain will contribute to a proper interaction between hBUB1 and hBUB3. This will probably explain the dominant negative nature of these defects.
Materials and methods
Cells
The following leukemia cell lines were used: K562, Molt3, Molt4, CEM, H9, HL60, KG1, and KG 1a. All except HL60 were grown in RPMI1640 supplemented with 10% fetal calf serum and antibiotics. HL60 was cultured in RPMI1640 with 20% fetal calf serum. The breast cancer cell lines used were: MCF7, MD231, MD435, MD453, MD483, T47D and the breast epithelial cell line HBL100. The breast cell lines were cultured in Dulbecco's Modified Eagle's Medium containing 10% fetal calf serum and antibiotics. Bone marrow aspirates or peripheral blood from leukemia and lymphoma patients were separated by Ficol gradient centrifugation and were then proceeded for RNA extraction.
Reverse transcription-polymerase chain reaction (RT -PCR)
Total cell RNA was extracted with acid-guanidinium-phenolchloroform method. Single-stranded cDNA was synthesized with SuperScript preamplification system (Gibco Life-Technologies) following the protocol provided by the vendor. Since the coding sequence of hBUB1 gene contains close to 3.2 kb to generate hBUB1 cDNA, three overlapping primer pairs were used for RT -PCR that covered from 5' to 3' end of the kinetochore localization (fragment A), central (fragment B), and kinase (fragment C) domains respectively. The sequences of these primers are: forward primer for the A fragment: 5'-ATGGACACCCCGGAAAATGTCCTTCA-3', the reverse primer for the A fragment: 5'-AGCATCTTT-GCTGGCCACTGCAAACATGGAGTCTGTTACT-3'. The forward primer for the B fragment: 5'-GTGGAGACATCC-CATGAGGATC-3', the reverse primer for the B fragment: 5'-GG AT CTT CT GCA ATG GC AGCG-3'. The forward primer for the C fragment: 5'-AGAGAAAAGCCCAAAA-CAG GCC TTG TCG TCT CAC ATG TAT-3'. The reverse primer for the C fragment: 5'-TTATTTTCGTGAACGCT-TAC ATT CTA AGA GCA GTA CAA TA-3'. PCR reaction mixtures without Taq polymerase were incubated at 708C for 2 min, 1 ml of Taq polymerase was then added to the mixtures. The cycle condition was as follows: 35 cycles of 958C for 1 min, 568C for 1 min and 728C for 1 min. After the last cycle reaction was continued at 728C for 8 min. At the end of PCR, 5 -10 ml of PCR products were digested with or without EcoRI, then analysed by electrophoresis in 1% agarose gel.
Genomic PCR
To examine the deletion at the cell DNA level, leukemia cell DNA from T-ALL patients and cell DNA from peripheral blood of normal individual were used as templates. The forward primer: 5'-GGTTCAGAGCTTTCTGGAGTGATA-TCTTCA-3' and reverse primer: 5'-CCCATTGCTCATGCT-TTCTCCGTTGATTGT-3' were used in a PCR programed as for RT -PCR described above.
Cloning and sequencing of hBUB1 cDNA
The PCR products were purified by a QIAgene PCR purification kit. The purified cDNA fragments were carried out either by direct DNA sequence or cloned into TA cloning vector (Promega). The plasmid DNA was then purified for further analysis.
Mitotic index analysis
The method adopted was modified from Hoyt et al., 1990 . Briefly, nocodazole was added to the culture to a final concentration of 0.2 mg/ml. Cells were harvested at 6 h intervals and fixed with 3.7% formaldehyde for 10 min. After the removal of formaldehyde, cells were rinsed three times with PBS for 5 min each time. The cells were then incubated with DAPI labeling solution (50 mg/ml) for 1 -5 min at room temperature. DAPI was then removed and cells were rinsed twice with PBS. The cells were examined by fluorescence microscopy and scored for cells arrested at metaphase. At least 200 cells were counted in a single experiment. The indices represented an average of two to three experiments.
Expression of wild type and mutant hBUB1 in cells and their effect in metaphase arrest
To construct vector expressing hBUB1 cDNA hBUB1 A fragment cloned into pGEM-T easy vector were digested with BsmF1 and Spe1. The hBUB1 B fragment from BsmF1 to Spe1 was ligated A to form hBUB1 AB plasmid. The hBUB1 AB plasmid was then digested with EcoNI and Spe1 to remove the 3' overlapping fragment. The hBUBIC plasmid was digested with EcoNI and Spe1 and the 3' hBUB1 sequence was ligated to hBUB1 AB to form the full length wild type or mutant hBUB1 cDNA. These full length cDNAs in pGEM-T were digested with Noti and inserted into pcDNA3 to form expression vector. These vectors were electrophorased into normal cells, treated with nocodazole, and scored for metaphase-arrested cells.
Fluorescent antibody staining for hBUB1
To prepare antibody against hBUB1, the cDNA representing N terminal 160 amino acid of hBUB1 was inserted into His tag vector pET. The recombinant protein was affinity purified and used to immunize rabbits. The primary antibody (at 1 : 400 dilution) was used to stain nocodazole treated HL60 cells and FITC conjugated goat anti rabbit IgG was used (at 1 : 50 dilution) as a secondary antibody. After antibody staining the cells were stained with DAPI to reveal the nuclei.
Interaction between hBUB1 and hBUB3
The entire coding sequence of hBUB3 was cloned into expression vector GEX-KG. The recombinant protein was bound to glutathione sepharose bead. The kinetochore localization domains of wild type and mutant hBUB1 were cloned into pGEM3z vector (Promega) and 35S labeled hBUB1 proteins were synthesized using TNT Coupled Reticulocyte Lysate System (Promega). Equal counts of radio-labeled proteins were mixed with GST-hBUB3 beads. After extensive washing the bound proteins were analysed by SDS -PAGE. The gel was then dried and analysed with Phosphoimager.
